Patterns of missing mini mental status exam (MMSE) in radiation therapy oncology group (RTOG) brain cancer trials

K Bae1, D W Bruner, S Baek

  • 1Statistics Department, Radiation Therapy Oncology Group, 1818 Market St. Suite 1600, Philadelphia, PA 19103, USA. kbae@phila.acr.org

Insights

Incomplete Mini Mental Status Exam (MMSE) data is common in brain cancer trials, with unknown reasons often cited. Addressing patient and institutional factors can improve data collection for more reliable neurocognitive assessments.

Area of Science:

  • Neuro-oncology
  • Clinical Trial Methodology
  • Cognitive Assessment

Background:

  • The Mini Mental Status Exam (MMSE) is frequently used in Radiation Therapy Oncology Group (RTOG) brain cancer trials.
  • Understanding patterns of incomplete MMSE data is crucial for improving trial data quality and interpretation.

Purpose of the Study:

  • To identify patient factors associated with incomplete MMSE assessments in RTOG brain cancer trials.
  • To explore optimal MMSE data collection schedules and potential biases in neurocognitive evaluations.

Main Methods:

  • Analysis of MMSE compliance patterns (Complete, Monotone drop-out, All missing, Mixed) in 1,957 patients across eight RTOG brain cancer trials.
  • Comparison of patient characteristics and reasons for missing data among different compliance patterns.
  • Statistical adjustment for factors like age, treatment type, education, and Zubrod performance status (ZPS).

Main Results:

  • Significant differences in missingness patterns were observed based on age, treatment type, education, and ZPS (P < 0.001).
  • While 92% of patients had at least one MMSE evaluation, only 7% had complete data; 49% followed a monotone drop-out pattern.
  • RT-only regimens showed higher evaluation rates compared to combined RT + other treatments.
  • Institutional error and patient refusal were common known reasons for missing data, though often unspecified.
  • Small, non-persistent differences in baseline MMSE scores were noted across missing patterns after adjustments.

Conclusions:

  • Incomplete MMSE data is prevalent in brain cancer trials, often due to unspecified reasons, posing a risk of bias.
  • Improving compliance may involve addressing institutional adherence to schedules and patient-related barriers, including educational and health status.
  • Further research is needed to understand and mitigate factors influencing neurocognitive data collection in clinical trials.

Related Concept Videos